BioSpace News Archive

Compugen Ltd. announced today that it expects to receive a milestone payment of $7.5 million from AstraZeneca, after AstraZeneca dosed the first patient in its ARTEMIDE Phase 2 study with AZD2936, a PD-1/TIGIT bispecific antibody derived from COM902, Compugen’s clinical-stage anti-TIGIT antibody.

Grey Wolf Therapeutics today announced it has entered into a clinical supply agreement with Regeneron for their PD-1 inhibitor Libtayo® (cemiplimab).

Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that it has entered into a direct 5-year agreement with Smart Automated Retail Network to supply immune support supplements for the expanding unattended automated retail market on an exclusive basis worldwide.

Ginkgo Bioworks Holdings, Inc. today announced the sale of shares of its Class A common stock for gross proceeds of approximately $100 million to BTIG, LLC, as the underwriter in the registered public offering of those shares.

Thorne HealthTech, Inc. today announced it will participate in a fireside chat and also meet with investors at the upcoming Evercore ISI HEALTHCONx Conference.

InnerScope Hearing Technologies Inc., an emerging and disruptive leader in the Over-the-Counter hearing aid space announced its financial results for third-quarter ended September 30, 2022.

Gracell Biotechnologies Inc today announced that its FasTCAR Autologous CAR-T Platform was named the winner of the Biotech Innovation category of the 2022 Fierce Life Sciences Innovation Awards.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced that its Life Science business sector is investing more than $ 286 million in its biosafety testing capacity at the company’s site in Rockville, Maryland, USA.

Freedom Biosciences today announced the appointment of David Hough, MD, as Chief Medical Officer.

InvisiShield Technologies Ltd., a pre-clinical-stage biotechnology company focused on developing intranasal preventives for major disease-causing respiratory viruses announced the appointment of Warner C. Greene, M.D., Ph.D., as President and Chief Scientific Officer.